VRTX
Income statement / Annual
Last year (2024), Vertex Pharmaceuticals Incorporated's total revenue was $11.02 B,
an increase of 11.66% from the previous year.
In 2024, Vertex Pharmaceuticals Incorporated's net income was -$535.60 M.
See Vertex Pharmaceuticals Incorporated,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$11.02 B |
$9.87 B |
$8.93 B |
$7.57 B |
$6.21 B |
$4.16 B |
$3.05 B |
$2.49 B |
$1.70 B |
$1.03 B |
| Cost of Revenue |
$1.53 B
|
$1.26 B
|
$1.08 B
|
$904.20 M
|
$736.30 M
|
$547.76 M
|
$409.54 M
|
$275.12 M
|
$210.46 M
|
$125.54 M
|
| Gross Profit |
$9.49 B
|
$8.61 B
|
$7.85 B
|
$6.67 B
|
$5.47 B
|
$3.62 B
|
$2.64 B
|
$2.21 B
|
$1.49 B
|
$906.79 M
|
| Gross Profit Ratio |
0.86
|
0.87
|
0.88
|
0.88
|
0.88
|
0.87
|
0.87
|
0.89
|
0.88
|
0.88
|
| Research and Development Expenses |
$3.63 B
|
$3.16 B
|
$2.54 B
|
$3.05 B
|
$1.83 B
|
$1.75 B
|
$1.42 B
|
$1.32 B
|
$1.05 B
|
$996.17 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$401.43 M
|
$352.58 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$31.40 M
|
$24.50 M
|
| Selling, General & Administrative Expenses |
$1.46 B
|
$1.14 B
|
$944.70 M
|
$840.10 M
|
$770.46 M
|
$658.50 M
|
$557.62 M
|
$496.08 M
|
$432.83 M
|
$377.08 M
|
| Other Expenses |
$4.63 B
|
$475.50 M
|
-$164.80 M
|
$4.90 M
|
$296.42 M
|
$192.18 M
|
-$790,000.00
|
-$81.38 M
|
$4.13 M
|
-$6.71 M
|
| Operating Expenses |
$9.72 B
|
$4.78 B
|
$3.49 B
|
$3.89 B
|
$2.60 B
|
$2.41 B
|
$1.97 B
|
$1.82 B
|
$1.48 B
|
$1.37 B
|
| Cost And Expenses |
$11.25 B
|
$6.04 B
|
$4.57 B
|
$4.80 B
|
$3.34 B
|
$2.96 B
|
$2.38 B
|
$2.10 B
|
$1.69 B
|
$1.50 B
|
| Interest Income |
$598.10 M
|
$614.70 M
|
$144.60 M
|
$4.90 M
|
$22.24 M
|
$63.68 M
|
$0.00
|
$11.75 M
|
$0.00
|
$0.00
|
| Interest Expense |
$30.60 M
|
$44.10 M
|
$54.80 M
|
$61.50 M
|
$58.15 M
|
$58.50 M
|
$34.12 M
|
$57.55 M
|
$81.43 M
|
$84.21 M
|
| Depreciation & Amortization |
$207.20 M
|
$181.30 M
|
$148.30 M
|
$125.60 M
|
$109.52 M
|
$106.94 M
|
$72.42 M
|
$61.40 M
|
$61.40 M
|
$62.34 M
|
| EBITDA |
$486.30 M |
$4.61 B |
$4.44 B |
$2.92 B |
$3.28 B |
$1.56 B |
$706.78 M |
$103.26 M |
$75.46 M |
-$411.25 M |
| EBITDA Ratio |
0.04
|
0.47
|
0.49
|
0.37
|
0.51
|
0.35
|
0.22
|
0.13
|
0.01
|
-0.46
|
| Operating Income Ratio |
-0.02
|
0.44
|
0.48
|
0.37
|
0.46
|
0.29
|
0.21
|
0.05
|
0.01
|
-0.45
|
| Total Other Income/Expenses Net |
$481.40 M
|
$72.30 M
|
-$75.00 M
|
-$51.70 M
|
$62.80 M
|
$197.42 M
|
-$34.91 M
|
-$138.93 M
|
-$77.30 M
|
-$90.92 M
|
| Income Before Tax |
$248.50 M
|
$4.38 B
|
$4.23 B
|
$2.73 B
|
$3.12 B
|
$1.39 B
|
$600.24 M
|
-$15.69 M
|
-$67.37 M
|
-$559.58 M
|
| Income Before Tax Ratio |
0.02
|
0.44
|
0.47
|
0.36
|
0.5
|
0.34
|
0.2
|
-0.01
|
-0.04
|
-0.54
|
| Income Tax Expense |
$784.10 M
|
$760.20 M
|
$910.40 M
|
$388.30 M
|
$405.15 M
|
$218.11 M
|
-$1.49 B
|
-$107.32 M
|
$16.67 M
|
$30.38 M
|
| Net Income |
-$535.60 M
|
$3.62 B
|
$3.32 B
|
$2.34 B
|
$2.71 B
|
$1.18 B
|
$2.10 B
|
$263.48 M
|
-$112.05 M
|
-$558.12 M
|
| Net Income Ratio |
-0.05
|
0.37
|
0.37
|
0.31
|
0.44
|
0.28
|
0.69
|
0.11
|
-0.07
|
-0.54
|
| EPS |
-2.08 |
14.05 |
12.97 |
9.09 |
10.44 |
4.58 |
8.25 |
1.06 |
-0.46 |
-2.32 |
| EPS Diluted |
-2.08 |
13.89 |
12.82 |
9.01 |
10.29 |
4.51 |
8.09 |
1.04 |
-0.46 |
-2.31 |
| Weighted Average Shares Out |
$257.50 M
|
$257.70 M
|
$256.10 M
|
$257.70 M
|
$259.84 M
|
$256.73 M
|
$254.29 M
|
$248.86 M
|
$243.59 M
|
$240.84 M
|
| Weighted Average Shares Out Diluted |
$257.90 M
|
$260.50 M
|
$259.10 M
|
$259.90 M
|
$263.40 M
|
$260.67 M
|
$259.19 M
|
$253.23 M
|
$244.69 M
|
$241.31 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
